|Last Price$93.90||Day Change (%)-0.95%|
|Open Price$93.84||Day Change ($)-0.90|
|Day Range93.64–94.17||52-Week Range72.77–95.50|
As of Fri 09/19/2014 04:31 PM EST | USD
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
The company's diverse operating divisions and robust pipeline should lead to steady growth.
Novartis up, Iliad drops: European movers
UPDATE: Novartis climbs, Iliad drops: European movers
EUROPE MARKETS: Novartis Up, Iliad Drops: European Movers
EUROPE MARKETS: Novartis Climbs, Iliad Drops: European Movers
UPDATE: These 10 boring stocks will beat your portfolio
Research and Markets: Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
Top managers continue to focus on higher-quality dividend-paying stocks in a fully valued market.
Research and Markets: Global Moderate Psoriasis Therapeutics Pipeline Report 2014 - 17 Companies & 23 Drug Profiles